doi:10.19982/j.issn.1000-6621.20240173

Abstract

CLC Number:

R521

References 32

[1]	国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 国家代谢性疾病临床医学研究中心, 等. 结核病与糖尿病共病的治疗管理专家共识. 中国防痨杂志, 2021, 43(1): 12-22. doi:10.3969/j.issn.1000-6621.2021.01.004.
[2]	Meng F, Lan L, Wu G, et al. Impact of diabetes itself and glycemic control status on tuberculosis. Front Endocrinol (Lausanne), 2023, 14: 1250001. doi:10.3389/fendo.2023.1250001.
[3]	Rehman AU, Khattak M, Mushtaq U, et al. The impact of diabetes mellitus on the emergence of multi-drug resistant tuberculosis and treatment failure in TB-diabetes comorbid patients: a systematic review and meta-analysis. Front Public Health, 2023, 11: 1244450. doi:10.3389/fpubh.2023.1244450.
[4]	Liu YH, Guo Y, Xu H, et al. Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury. Infect Drug Resist, 2021, 14: 3667-3671. doi:10.2147/IDR.S326386.
[5]	Baluku JB, Nuwagira E, Bongomin F, et al. Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities. Int J Tuberc Lung Dis, 2021, 25(7): 537-546. doi:10.5588/ijtld.21.0034. pmid: 34183098
[6]	Page ID, Byanyima R, Hosmane S, et al. Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. Eur Respir J, 2019, 53(3): 1801184. doi:10.1183/13993003.01184-2018.
[7]	Denning DW, Page ID, Chakaya J, et al. Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings. Emerg Infect Dis, 2018, 24(8): e171312. doi:10.3201/eid2408.171312.
[8]	Denning DW, Cole DC, Ray A. New estimation of the prevalence of chronic pulmonary aspergillosis (CPA) related to pulmonary TB-a revised burden for India. IJID Reg, 2022, 6: 7-14. doi:10.1016/j.ijregi.2022.11.005.
[9]	Bongomin F, Olum R, Kibone W, et al. Prevalence of chronic pulmonary aspergillosis along the continuum of pulmonary tuberculosis care: A protocol for a living systematic review and meta-analysis. PLoS One, 2023, 18(12): e0294634. doi:10.1371/journal.pone.0294634.
[10]	郭静, 沈银忠. HIV感染/AIDS合并结核病的临床及免疫学特点研究进展. 诊断学理论与实践, 2021, 20(4): 401-406. doi:10.16150/j.1671-2870.2021.04.014.
[11]	World Health Organization. WHO operational handbook on tuberculosis (Module 1: prevention): tuberculosis preventivetreatment. Geneva: World Health Organization, 2020.
[12]	World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment,Service Delivery and Monitoring: Recommendations for a Public Health Approach. Geneva: World Health Organization, 2021.
[13]	Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV[EB/OL].[2024-04-29]. https://clinicalinfo.hiv.gov/en/guidelines/adult-andadolescent-opportunistic-infection.
[14]	Namale PE, Abdullahi LH, Fine S, et al. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol, 2015, 10(6): 1077-1099. doi:10.2217/fmb.15.9. pmid: 26059627
[15]	Meintjes G, Stek C, Blumenthal L, et al. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. N Engl J Med, 2018, 379(20): 1915-1925. doi:10.1056/NEJMoa1800762.
[16]	World Health Organization. WHO consolidated guidelines on tuberculosis:Module 1:prevention: tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
[17]	Shachor Y, Schindler D, Siegal A, et al. Increased incidence of pulmonary tuberculosis in chronic interstitial lung disease. Thorax, 1989, 44(2): 151-153. doi:10.1136/thx.44.2.151. pmid: 2929001
[18]	Chung MJ, Goo JM, Im JG. Pulmonary tuberculosis in patients with idiopathic pulmonary fibrosis. Eur J Radiol, 2004, 52(2): 175-179. doi:10.1016/j.ejrad.2003.11.017. pmid: 15489076
[19]	Wong C, Sahni S, Cheema MAI, et al. Mycobacterium tuberculosis Infection in the Setting of Interstitial Lung Disease: Coincidence or Bad Luck?. Cureus, 2018, 10(10): e3391. doi:10.7759/cureus.3391.
[20]	Lee YH, Cha SI, Lim JK, et al. Clinical and radiological features of pulmonary tuberculosis in patients with idiopathic pulmonary fibrosis. Respir Investig, 2019, 57(6): 544-551. doi:10.1016/j.resinv.2019.08.001.
[21]	Ogawa K, Kurosaki A, Miyamoto A, et al. Clinicoradiological Features of Pulmonary Tuberculosis with Interstitial Pneumonia. Intern Med, 2019, 58(17): 2443-2449. doi:10.2169/internalmedicine.2341-18.
[22]	Shah SN, Gajwani BW, Dave BT. Idiopathic diffuse interstitial lung disease with tuberculosis. Indian J Chest Dis, 1967, 9(4):229-232. pmid: 5633706
[23]	Dias VL, Storrer KM. Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression. J Bras Pneumol, 2022, 48(2): e20210382. doi:10.36416/1806-3756/e20210382.
[24]	Moran E, Baharani J, Dedicoat M, et al. Risk factors associated with the development of active tuberculosis among patients with advanced chronic kidney disease. J Infect, 2018, 77(4): 291-295. doi:10.1016/j.jinf.2018.06.003. pmid: 29928915
[25]	GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017, 2020, 395(10225): 709-733. doi:10.1016/S0140-6736(20)30045-3.
[26]	Alemu A, Bitew ZW, Diriba G, et al. Tuberculosis incidence in patients with chronic kidney disease: a systematic review and meta-analysis. Int J Infect Dis, 2022, 122: 188-201. doi:10.1016/j.ijid.2022.05.046. pmid: 35609860
[27]	Vikrant S. Tuberculosis in dialysis: Clinical spectrum and outcome from an endemic region. Hemodial Int, 2019, 23(1): 88-92. doi:10.1111/hdi.12693. pmid: 30289617
[28]	Vikrant S. Clinical profile of tuberculosis in patients with chronic kidney disease: A report from an endemic Country. Saudi J Kidney Dis Transpl, 2019, 30(2):470-477. doi:10.4103/1319-2442.256854. pmid: 31031383
[29]	中国医院协会血液净化中心管理分会专家组. 中国成人慢性肾脏病合并结核病管理专家共识. 中国血液净化, 2016, 15(11): 577-586. doi:10.3969/j.issn.1671-4091.2016.11.001.
[30]	British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee, Milburn H, Ashman N, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax, 2010, 65(6): 557-570. doi:10.1136/thx.2009.133173.
[31]	中华医学会结核病学分会. 慢性肾脏病合并结核病的治疗专家共识(2022版). 中华结核和呼吸杂志, 2022, 45(10):996-1008. doi:10.3760/cma.j.cn112147-20220327-00241.
[32]	Xiao J, Ge J, Zhang D, et al. Clinical Characteristics and Outcomes in Chronic Kidney Disease Patients with Tuberculosis in China: A Retrospective Cohort Study. Int J Gen Med, 2022, 15: 6661-6669. doi:10.2147/IJGM.S367090. pmid: 36016982

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 32

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443.
[2]	Li Min, Yao Yushan, Qiao Haixia, Lei Hong. Association between pulmonary tuberculosis and the gut microbiota: treatment strategies [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 520-526.
[3]	Song Yunlin, Buzukela Abuduaini, Wang Guirong, Zhang Jiyuan, Lu Xiaobo. Research progresses on the role and mechanism of calcium-binding protein S100A12 and neutrophil extracellular trap formation in lung injury of severe pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 513-519.
[4]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[5]	Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424.
[6]	An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438.
[7]	Li Leilei, Shi Lei, Wang Lin, Li Hongwei, Xu Liran, Pang Yu, Song Yanzheng. Clinical characteristics analysis of HIV-infected cases diagnosed with tuberculosis after surgery due to pulmonary nodules [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 266-273.
[8]	Gong Sheng, Wang Ning, Li Dan, Li Gang, Liu Yu, Jiang Liangshuang, Yao Xiaojun. Comparative study of fluorescence staining method and inflation-deflation method for thoracoscopic pulmonary tuberculosis segmentectomy [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 292-297.
[9]	Shi Yuru, Gu Dejian, Wu Jing, Liu Ting, Qin Linghan, Yue Li, Qi Yingjie. Diagnostic value of probe capture-based targeted next-generation sequencing and metagenomic next-generation sequencing for detecting Mycobacterium tuberculosis in bronchoalveolar lavage fluid [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 305-311.
[10]	Song Feier, Mao Yanjun, Xia Qiuyue, Zhou Yang, Lin Huan. The prevalence and influencing factors of post-tuberculosis lung disease: A Meta-analysis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 322-330.
[11]	Yang Haixia, Zhang Xiaoyan, Huang Yi, Li Qiu. Effective and safety of concurrent intensity-modulated radiotherapy and anti-tuberculosis chemotherapy in patients with active pulmonary tuberculosis comorbid with thoracic tumor [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 312-321.
[12]	Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan. Safety of extended delamanid use in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168.
[13]	Gao Li, Chen Shengyu, Zhang Wenqian, Li Dan, Zhang Guoqin. Investigation on ability of conducting tuberculosis surveillance among four types of high-risk population in Tianjin public hospitals [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 195-200.
[14]	Wang Dafu, Ma Xiaoxue, Wang Yun, Li Fudong, Rao Wen, Gong Tingting, Li Shijun, Li Jinlan. Analysis of risk factors for patient delay and adverse treatment outcomes among patients with pulmonary tuberculosis and diabetes mellitus in Guizhou Province, 2016—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 201-209.
[15]	Qiu Yong, Quan Zhuo, Qu Rong, Tian Fajun, Li Meng, Wang Gengsheng, Wang Ya, Guo Mingcheng, Gao Qian. Evaluation of different tuberculosis diagnostic tools for detecting patients in a primary-level clinic in rural China: a real-world retrospective study [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 181-188.